Publisher： Adis International
ISSN： 1173-5503
Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.482, 2005-01, pp. : 3-3
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
IV vancomycin to oral linezolid switch potentially cost saving
Inpharma, Vol. 1, Iss. 1400, 2003-01 ,pp. :
Access to resources
Recommend
IV vancomycin to oral linezolid switch potentially cost saving
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 425, 2003-01 ,pp. :
Intensive MRSA control programme cost saving in Sweden
Inpharma, Vol. 1, Iss. 1463, 2004-01 ,pp. :
Economic burden of MRSA-related NP substantial
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 668, 2012-01 ,pp. :
Linezolid best value in MRSA SSI
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 524, 2007-01 ,pp. :